Not Just Living, But Thriving, With Targeted Therapy

When Bekah Cunningham completed the final mile of the Appalachian Trail in November 2019, it was the culmination of an incredible journey of far more than the nearly 2,200 miles she’d covered over seven months. It was even more incredible considering that three years earlier, the then-29-year-old was told she had lung cancer and only had months to live. After her diagnosis, Cunningham sought a second opinion at Dana-Farber, where she went on a targeted therapy drug that changed everything for her.

Risk and Prevention

• Should I Worry About a Lump Under the Armpit?
• What’s the Difference Between Melanoma and Skin Cancer/Carcinoma?

See All >

Dana-Farber Research

• Study Overturns Dogma About Cell Division; Could Unlock New Cancer Drug Target
• Patient with Lung Cancer Participates in ‘Practice-Changing’ Immunotherapy Research

See All >

Recent Articles

• Cancer Screening for the LGBTQ+ Community
• Patient with Lung Cancer Participates in ‘Practice-Changing’ Immunotherapy Research

See All >

COVID-19 Information

• COVID-19 Vaccines for Cancer Patients and Survivors: What We Know
• What are the Symptoms of the Coronavirus (COVID-19)?

See All >

Advances in Myeloma, Breast Cancer, and Clinical Trials Equity: A Dana-Farber Research Update

Results of several phase 3 trials and dozens of other studies led by Dana-Farber researchers were presented online and in person June 3-7 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting.